Dr. Jordi Ordóñez-Llanos is an expert in clinical biochemistry and, in particular, biomarkers of cardiovascular risk and disease. He is a Professor of Clinical Biochemistry at the Universidad Autonóma and emeritus senior consultant on Clinical Biochemistry at Hospital de la Santa Creu i Sant Pau, both in Barcelona, and the Technical Director of the Biochemistry and Molecular Pathology Foundation. He served as a consultant for the Committee on Clinical Applications of Cardiac Biomarkers of the International Federation of Clinical Chemistry up to the year 2022, after chairing the group for 6 years. Lastly, he is a fellow of the Academy for Diagnostic and Laboratory Medicine (formerly the Academy of the American Association of Clinical Chemistry).

Dr. Joan Carles Escolà-Gil currently works as a Senior Researcher at the Institut de Recerca Sant Pau, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain. He is also a Collaborating Professor at the Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona. He was a visiting professor at the Wihuri Research Institute in 2010 and a visiting professor at the Finnish Institute for Health and Welfare, Helsinki, Finland, in 2015. He graduated from the University of Barcelona in 1991. As a principal investigator, his main line of research focuses on the development and metabolic characterization of genetically modified mice as models of dyslipidemia (and more specifically, HDL alterations), obesity, diabetes, and arteriosclerosis. In addition, he also works on projects focused on the study and clinical, biochemical, and genetic characterization of patients with metabolic alterations that pose a cardiovascular risk, especially dyslipidemia. This line is more closely linked to clinical research linked to healthcare activity.